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Abstract
Background: Morphologic criteria which might help to support the need for a preventive strategy
for early detection of rectal cancer were analysed. Population-based data on rectal adenomas with
high-grade dysplastic changes (n = 199) and invasive adenocarcinomas (n = 912) registered by the
national Morphologic Tumour Registry (MTR) and diagnosed in a central department of pathology
in Luxembourg between 1988 and 1998 were considered.
Methods: The analysis concerned time trends in frequency, crude incidence, tumour-stage, the
rectal "high-grade" adenoma/invasive adenocarcinoma-ratio and the survival rates.
Histopathological tumour-stage parameters (UICC/AJCC, 1997) in a consecutive series of 641
resected rectal cancers and their relationship with the observed patient survival are investigated.
Results: The majority of invasive adenocarcinomas are diagnosed at a late stage (i.e. Stage II and
III) into contrast with the highly significant increase (355 %) in frequency of rectal high-grade
adenomas (Stage 0). During the two-time periods 1988–1992 and 1994–1998 Stage I and Stage IV-
cases decreased by 11 % and 47 % respectively. Tumour-stage correlates with prognosis. The rectal
high-grade adenoma / invasive adenocarcinoma-ratio improved significantly over the last five years.
Conclusion: Over the study period, there has been a highly significant rise in the incidence of
resected rectal adenomas with high-grade intraepithelial neoplasia. The ratio of early tumours to
invasive cancers has risen while the numbers of colonoscopies and rectoscopies remained
unchanged respectively decreased. As the number of advanced tumour-stages remained stable,
mass-screening procedures focusing on the fifty to sixty age group should be reinforced.
Introduction
As described by the TNM-system and confirmed by many
multivariate analyses the prognosis of patients after
tumour-resection for cure (R0) of colorectal cancer (CRC)
is predominantly influenced by the anatomical extend of
cancer [1–9].
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In view of a national CRC-screening pilot-project, the
authors have collected descriptive epidemiological data of
the rectal cancer (i.e. frequency, crude incidence, age dis-
tribution, age standardized incidence rates, tumour-stage,
residual tumour tissue, number of the senior surgeons
involved, number of colonoscopies realized, number of
rectoscopies, mortality rates) for different time spans in
the Grand-Duchy of Luxembourg (Western Europe).
Evaluating the data from the period 1988–1998, argu-
ments and criteria to develop an alternative strategy for
early detection of colorectal cancer in a defined area (Lux-
embourg) with a 'liberal' medical care system and without
academic medical institutions have to be looked for.
Methods
Between January 1rst 1988 and December 31 1998 the
Morphologic Tumour Registry (MTR) in Luxembourg reg-
istered 199 new cases of rectal "high-grade" adenomas
and 912 new consecutive cases of invasive rectal adeno-
carcinomas in a population increasing from 374,900 in
1988 to 429,200 in 1998, an average increase of 1.3% per
year [10–12]. The registration of rectal high-grade adeno-
mas and invasive adenocarcinomas diagnosed by 9
pathologists in the only department of pathology in the
country is mandatory. In this study patients of all nation-
ality living in Luxembourg were evaluated. Only new pri-
mary tumours were considered. Recurrent disease,
synchronous or metachronous adenomas or adenocarci-
nomas, mesenchymal malignant tumours, epidermoid
tumours of the anorectal junction, metastatic lesions and
high-grade adenomas at the same site were excluded the
latter being considered separately. The rectal cancers (RC)
were removed by 45 senior surgeons.
Excluding invasive cancers diagnosed only by biopsy,
there were 694 surgical specimens allowing an interpreta-
tion in function of the tumour depth of penetration of the
rectal wall (pT) [1–3,9,13]. In analogy to the former orig-
inal Dukes-System 641 surgical resection specimens per-
mited an analysis in relation to the lymph node-status by
the tumour-stage (Stage I to IV) supported by the Union
International Contre le Cancer (UICC) and the American
Joint Committee on Cancer (AJCC) [1–4,14]. So the strat-
ification by stage (Table 1) required the exclusion of
patients diagnosed by biopsy forceps only, patients who
underwent only polypectomy without segmental resec-
tion or rectal amputation and patients with known preop-
erative non-surgical, debulking treatments. By this way an
evaluation of our data in relation to the evaluable pres-
ence or absence of lymph nodes (i.e. polypectomy,
transanal resection versus classic amputation) could be
realized.
The R-classification was performed by conventional meth-
ods [3–9] and focused on the loco-regional extend. The
different categories were defined as follows:
Rx = presence of residual tumour cannot be assessed; R0 =
no residual tumour; R1 = microscopically residual
tumour; R2 = macroscopically residual tumor [1].
To evaluate the survival rates in relation to the anatomical
extent 203 patients with RC only diagnosed by biopsy
without surgical resection had to be excluded previously
and were subject of a separate analysis.
The histopathological diagnoses of all lesions were real-
ized following the WHO-classification [15]. According to
the WHO-recommandations, we defined "high-grade"
adenomas as adenomas of tubular, villous or tubulo-vil-
lous histological type with high-grade intraepithelial neo-
plasia (i.e. dysplasia) [15,16]. This category includes, in
analogy to the pTis-class or stage 0 of the TNM-System,
cancer cells confined within the glandular basement
membrane (intraepithelial) or lamina propria (intramu-
cosal) with no extension through muscularis mucosa into
submucosa [1–3]. The staging according to the TNM-clas-
sification was completed with the residual tumour status
(R) [1,2,7–9]. Anatomically the rectum was defined as a
16 cm long segment between the ano-cutaneous line and
the sigmoid colon.
Table 1: Tumour-stage classifications and equivalences Dukes (1932) – TNM/UICC-AJCC (1987, 1992, 1997) 1–4,14
DUKES STAGE TNM degree of tumour extension
A I pT1 NO MO T1: submucosa
pT2 NO MO T2: muscularis propria
B* II pT3 NO MO T3: perirectal tissue
pT4 NO MO T4: others orangs or structures/visceral peritoneum
C* III anyT N1 MO N1: ≤ 3 regional lymph nodes
anyT N2 MO N2: > 3 regional lymph nodes
IV anyT anyN M1 M1: distant metastasis
*Dukes B is a composite of better (T3N0M0) and worse (T4N0M0) prognostic groups, as is Dukes C (anyT N1M0 and anyT N2M0)BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/27
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Patient survival was measured from the time of operation.
As expected survival rates of the 1990's of the Luxembour-
gish population were not yet available the calculation of
the relative survival rates was not possible. The observed
survival rates were analysed in relation to curative resec-
tion (i.e. R0-cases) and without distinction of the R-status
(R0, R1, R2, Rx included).
To compare our results with the data of other geographical
European regions published by the WHO in "Cancer in
five continents, volume VII" [17] the rectal cancers had to
be added to the cancers of the rectosigmoidal junction.
The statistical evaluations included the chi-square test
with a level of significance p < 0.05 and the life-table sur-
vival analysis. The age-standardized incidence rates were
calculated by the direct method, the standard error of the
age-standardized rates by the Poisson approximation
[18].
Results
The unequivocal histopathological diagnosis of 912 con-
secutive invasive rectal adenocarcinomas (RC) were pro-
vided from 203 samples obtained by biopsy only
(22.3%), 32 total polypectomy specimens (3.5%) and
677 surgical resection specimens (74.2%). The latter
allowed a stratification by stage according to the TNM
(UICC/AJCC)-classification [1–4]. 641 of these patients
with surgical treatment have had available survival fol-
low-up data.
The 912 invasive RC concerned 517 males (56.7%) and
395 females (43.3%), the M/F-ratio being 1.3:1. The age
distribution varied from 26 years to 95 years (mean: 68.9
years). The average, annual, all-ages incidence rate of rec-
tum cancer in Luxembourg over the period 1988–1998
was 20.7 per 100,000 both gender together, for males
23.8 per 100,000 and for females 17.6 per 100,000. The
average, annual, age-standardized incidence rate (ASR) of
rectum cancer (period 1988–1998) was 12.1 per 100,000
(12.1 +/- 0.4 with 95% confidence interval), for males
16.5 per 100,000 (16.5 +/- 1.1,95% confidence interval)
and for females 8.7 per 100,000 (8.7 +/- 0.5,95% confi-
dence interval).
The crude and age-standardized incidence rates in relation
to gender, did not significantly decrease (Figure 1). The
comparison of patients diagnosed in the 5-year periods
1988–1992 and 1994–1998 revealed a slight decrease of
the crude, age standardized incidence rates for both gen-
der from 12.6 to 11.9, for females from 7.7 to 7.5 and for
males from 17.1 to 15.8.
The time trend (1988–1998) of the invasive RC shows a
non significant increase of the frequency (p = n.s.). The
total number of invasive RC rose from 89 cases in the year
1988 to 95 cases in 1998. The number of RC in males grew
from 56 to 58 and in females from 33 to 37. Comparing
the two five-year periods 1988–1992 and 1994–1998
there was a slight increase in the absolute number of all
RC from 409 to 425 cases. The absolute number of RC in
males grew from 226 to 240 cases, in females from 183 to
185 cases.
Figure 2 shows the age distribution of all patients with a
morphologically confirmed invasive rectal adenocarci-
noma (n = 912). 5.6 % of the patients (51/912) had less
than 50 years of age, 15.9 % between 50 and 60 years;
29.2 % between 60 and 70 years; 31.3 % between 70 and
80 years and 18 % of the patients were 80 years and above.
Time trends in relation to the tumour-stages defined by
the TNM-System (UICC/AJCC) are represented in Figure
3. During the two five-year periods 1988–1992 versus
1994–1998 there is an highly significant increase of diag-
nosed stage 0 i.e. high-grade adenomas by 355 %. Stage I-
cases decreased by 11 % and Stage IV-cases by 47 %. Stage
II-cases increased by 6.6 %, Stage III by 35 %.
At the same period (1988 to 1998) 199 new cases of rectal
high-grade adenomas (Stage 0) have been diagnosed (Fig-
ure 4). If we compare the average of the rectal "high-grade
adenoma / invasive adenocarcinoma – ratio" of the five-
year periods 1988–1992 and 1994–1998 with a ratio
1:12,4 (33/409) versus 1:2,8 (150/425) there is a highly
significant improvement in the last decade (p < 0.001).
The overall observed survival rates of 912 patients with an
invasive rectal adenocarcinoma, diagnosed by biopsy or
polypectomy or surgical specimen and calculated by the
actuarial method (life-table) with a 95 % confidence
interval (c.i.) stratified by years are:first year 74 +/- 3 % (n
= 673/912); second year 59 +/- 3 % (n = 536/912); third
year 51 +/- 3 % (n = 463/912); forth year 46 +/- 3 % (n =
424/912) and after five years 43 +/- 3 % (n = 396/912).
In Table 2 the observed survival rates of 641 invasive rectal
adenocarcinomas stratified by the stage independent of
the residual tumour status (Rx, R0, R1 or R2). Table 3
shows the stratification of the observed 5-year survival
rates in relation to the stages TNM (UICC/AJCC) consid-
ering only the 488 patients operated for cure (R0).
(*The analysis of the observed survival rates concerning
the 203 patients with invasive rectal cancer diagnosed by
biopsy-forceps only reveals that 112 patients survived 12
months and 20 patients died in the first month, 43 within
the next 6 months and 28 in the period from the 6th to the
12th month. The age distribution of these patients showsBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/27
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that 13 had less than 50 years, 121 were aged between 50
and 79 years and 69 patients had more than 80 years.)
Table 4 documents the world age-standardized incidence
rates (ASR/W) of invasive rectal adenocarcinomas in the
Luxembourgish population (females and males) in com-
parison to other European countries not selected at ran-
dom but for geographical proximity or population-
density or socio-economic reasons.
To exclude an influence of changing colonoscopic diag-
nostic procedures in Luxembourg we analysed the data
gratefully made available by the National Health Fund
(NHF) [19] over the 4-year period 1992–1995. As repre-
sented in table 5, there were a non significant decrease in
the number of colorectal endoscopies, a non significant
increase in the number of colonoscopies with biopsy
examination whereas the number of rectoscopies
decreased significantly.
The mortality rates by rectal cancer of the last 15 years
(1984–1998) regrouped by 5-year periods are summa-
rized in table 6[20]. In the 1980's the mortality rates for
both gender decreased significantly, whereas in the 1990's
they remained stable.
Discussion
The incidence and crude incidence rates of the invasive
rectal adenocarcinomas in our series are comparable to
those of the limitrophe countries [17]. Knowledge of the
frequencies of rectal high-grade adenomas and of invasive
adenocarcinomas over years in a defined population and
area may provide essential informations and arguments
for the design of a colorectal cancer prevention program
[21]. Comparing two 5-year periods (1988–1992 and
1994–1998) in our series there are no significant changes
over time nor of the number of newly diagnosed invasive
rectal cancers (409 vs 425, p = n.s.) neither of their crude
incidences (120.6/100,000 vs 117.1/100,000, p = n.s.). A
similar time trend has been described by Jessup et al. [22]
Frequency of new invasive adenocarcinomas (n = 912 cases) Period 1988–1998 Figure 1
Frequency of new invasive adenocarcinomas (n = 912 cases) Period 1988–1998.
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evaluating (National Cancer Data Base Report) a total of
98,537 rectal and rectosigmoid junction adenocarcinoma
cases in the United States over the period 1985–1995.
The age distribution in our series reveals that mainly eld-
erly patients suffer from rectal cancer, whereas only 5.5%
(50/912) of the patients have less than 50 years [males
7.2% (37/516) and females 3.3% (13/396)].
The comparison of the mortality rates of rectal cancer in
Luxembourg over the last 15 years (Table 6) does denote
a significant decrease (p < 0.02) between the two first 5-
year periods (8.7/100,000 period 1984 – 1988 and 6.6 /
100,000 period 1989–1993) whereas during the two lat-
ter periods 1989 – 1993 and 1994 – 1998) there is no sig-
nificant decrease (p = n.s.) [20]. It is generally accepted
that stage at diagnosis is one of the strongest predictor of
prognosis [23,24]. In our series 18.1 % of the patients
(116/641) were diagnosed as Stage I. This number is com-
parable to the results from 1005 rectal cancer cases diag-
nosed between 1982 and 1987 and recorded by the
tumour-registries of Mallorca (Spain), Côte d'Or (France)
and Geneva (Switzerland) with 16 %, 21 % and 29 % of
Stage I-cases respectively [24]. Finn-Faivre et al. described
in a series of 1978 patients with rectal cancer between
1978–1993 that the proportion of patients with Stage I
cancer increased from 17.7 % to 30.6 % with a corre-
sponding decrease in those with more advanced disease
[25]. Unfortunately in Luxembourg the number of Stage I-
cases decreased by 11 %, that of advanced stages (i.e. Stage
II and Stage III) increased by 6.6 % and 35.0 % respec-
tively over the two 5-year periods 1988–1992 and 1994–
1998. Thus it seemed that too many late stage cases (Stage
II and Stage III) are diagnosed and that possibly the treat-
ment outcome of rectal cancers in Luxembourg during the
last decade has not improved significantly. This situation
needs further investigations.
Survival analysis in relation to the data of the different
patient-groups (i.e. all patients with morphologically ver-
Invasive rectal adenocarcinomas (n = 912) – age distribution – period 1988–1998 Figure 2
Invasive rectal adenocarcinomas (n = 912) – age distribution – period 1988–1998.
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ified rectal cancer diagnosis versus patients with polypec-
tomy and rectal resection or amputation stratified by stage
was undertaken (Table 2+3). The poorer prognosis corre-
lates with the advanced tumour-stages and the residual
tumour-classification, as described in the literature [7–
9,22–27]. The highly significant increase in the detection
of high-grade adenomas starting in 93 is due to the
increased experience of the established endoscopists in
Luxembourg since the late eighties. This has led to a better
surveillance of patients presenting with low-grade adeno-
mas and a better detection of high-grade adenomas. Pub-
lic awareness is less relevant as public information
campaigns have been carried out much later in Luxem-
bourg. In addition, a certain number of patients might not
have received additional adjuvant post-operative therapy.
This is especially due for radiation therapy (in some Stage
II and most Stage III patients), as this therapy was not
available in Luxembourg until the late nineties and many
patients were not able to travel abroad for personal or co-
morbidity reasons.
As summarized in Figure 4, we notice since 1992 a highly
significant increase of the diagnoses of high-grade adeno-
mas with a continuous improvement of the rectal high-
grade adenoma / invasive adenocarcinoma-ratio although
there was no significant increase of the number of
gastroenterologists [19] or reimbursement of endoscopi-
cal explorations cost by the National Health Fund at least
during the period 1992–1995 [19,21]. It could be
admitted that this improved ratio will lead over the next
decade to a falling incidence of invasive rectal cancer.
The improvement of the adenoma/adenocarcinoma-ratio
over time is an index of better quality of the endoscopic
explorations. This is due mainly because of two reasons:
first, the arrival of a new generation of better trained endo-
scopists in the late eighties and secondly, a better under-
standing of the preventive indications for endoscopies by
the practitioner as well as the general population.
High-grade adenomas (n = 199 cases) and rectal invasive adenocarcinomas (n = 641 cases) by stage (TNM/UICC – AJCC,  1997)3 Figure 3
High-grade adenomas (n = 199 cases) and rectal invasive adenocarcinomas (n = 641 cases) by stage (TNM/UICC – AJCC, 
1997)3
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Rectal high-grade adenoma / invasive adenocarcinoma-ratio: time-trend from 1988 to 1998; males and females; n = 199*/912  cases Figure 4
Rectal high-grade adenoma / invasive adenocarcinoma-ratio: time-trend from 1988 to 1998; males and females; n = 199*/912 
casest
Table 2: Rectal adenocarcinomas: observed survival rates calculated by the actuarialmethod (95% confidence interval) by stage (TNM/
UICC, 1997) [3] without distinctionof the R-status (R0, R1, R2, Rx) n = 641 cases
Stage I-IV Stage I* Stage II* Stage III* Stage IV*
n = 641 (100%) n = 116 (18.1%) n = 179 (27.9%) n = 270 (42.1%) n = 76 (11.9%)
1 year 78+/-3% (n = 503) 94+/-4% (n = 109) 88+/-5% (n = 157) 70+/-5% (n = 188) 64+/-11% (n = 49)
2 years 64+/-4% (n = 408) 90+/-6% (n = 104) 77+/-6% (n = 137) 50+/-6% (n = 135) 42% ** (n = 32)
3 years 54+/-4% (n = 346) 86+/-6% (n = 100) 65+/-7% (n = 117) 39+/-6% (n = 106) 30% ** (n = 23)
4 years 49+/-4% (n = 315) 86+/-6% (n = 100) 58+/-7% (n = 104) 36+/-6% (n = 97) 18% ** (n = 14)
5 years 46+/-4% (n = 292) 81+/-7% (n = 94) 55+/-7% (n = 98) 34+/-6% (n = 92) 11% ** (n = 8)
* only surgical specimens (n = 641 cases) with available survival data ** standard error omitted sample being too small
               *diagnoses by biopsy only are included;     High-Grade Adenomas        invasive Adenocarcinomas
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Table 3: Rectal adenocarcinomas – 5-year overall observed survival rates calculated by the actuarial (life-table) method (95% confidence 
interval) – curative resection (R0)*
5-year observed survival rates
Stage (I-IV) n = 488 cases (100%) 53 +/- 4% (n = 259)
Stage I n = 110 cases (23%) 82 +/- 7% (n = 90)
Stage II n = 140 cases (29%) 62 +/- 8% (n = 87)
Stage III n = 190 cases (39%) 40 +/- 7% (n = 76)
Stage IV n = 48 cases (10%) 13 +/- 9% (n = 6)
* excluded cases diagnosed by biopsy or polypectomy only
Table 4: Rectal cancer in the European Community: World age-standardized incidence rates [ASR(W)*]; 1988–1992
MALES FEMALES
F/Bas-Rhin 19.0 D/Saarland 10.9
NL/Maastricht 18.6 DK/Denmark 10.4
L/Luxembourg 17.6 NL/Maastricht 10.4
D/Saarland 17.3 L/Luxembourg 9.2
DK/Denmark 17.0 UK/South Western 9.0
A/Tyrol 14.8 F/Bas-Rhin 8.9
UK/South Western 14.2 A/Tyrol 8.9
CH/St. Gallen 14.1 I/Parma 8.8
E/Basque Country 13.5 S/Sweden 8.3
IRL/Southern 13.1 CH/St. Gallen 7.9
I/Parma 13.0 IRL/Southern 7.2
S/Sweden 12.1 SF/Finland 6.6
SF/Finland 10.5 E/Basque Country 6.4
* Cancer incidence in five continents. Vol. VII period 1988–199217
Table 5: Time trend of the number of colorectal 'endoscopical' procedures in Luxembourg (period 1992–1995)19
Total number of 
Colo-rectal Endoscopies
Colonoscopies with biopsy Rectoscopies
n = 30489 n/105* n = 11491 (37.7%**) n/105 n = 6787 (22.3%**) n/105
1992 n = 7621 1928.4 n = 2699 (35.4%**) 682.9 n = 1795 (23.6%**) 454.2
1993 n = 7867 1962.3 n = 2883 (36.6%**) 719.1 n = 1819 (23.1%**) 453.7
1994 n = 7590 1866.7 n = 2962 (39.0%**) 728.5 n = 1663 (21.9%**) 409.0
1995 n = 7411 1795.3 n = 2947 (39.8%**) 713.9 n = 1510 (20.4%**) 365.8
*) number per 100,000 persons at risk **) % in relation to all colorectal endoscopies
Table 6: Analysis of the mortality rates from all rectal adenocarcinomas of the last 15 years (1984–1998)20
Males Females both gender P-value*
1984–1988: 9.7/105 7.8/105 8.7/105 p < 0.02
1989–1993: 6.5/105 6.6/105 6.6/105 p = n.s.
1994–1998: 6.2/105 6.4/105 6.3/105
* level of significance 0.05BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/27
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Conclusion
The classic mass-screening programmes of colorectal can-
cers being controversially discussed, it nevertheless seems
to be necessary to reinforce early detection by means of a
systematic information of physicians and patients focus-
ing on the fifty and sixty age group in view to decrease the
number of advanced tumour-stage.
For the future, the actual adenoma/adenocarcinoma-ratio
of 1:2,9 (average of the last 5 years) will be accepted as
"golden standard" to assess the quality of an "Endoscopic
National Program of Prevention of colo-rectal cancers" in
collaboration with the governmental authorities.
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